Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients
Korean Journal of Hematology
;
: 58-61, 2010.
Artigo
em Inglês
| WPRIM
| ID: wpr-721026
ABSTRACT
BACKGROUND:
Iron overload is a predictable and life-threatening complication in patients dependent on the regular transfusion of RBCs. The aims of this study were to investigate the efficacy and safety of deferiprone in a variety of pediatric hematologic and/or oncologic patients with a high iron overload.METHODS:
Seventeen patients (age 1.1-20.4 years; median 10.6 years) from 7 hospitals who were treated with deferiprone from 2006 to 2009 were enrolled in this study. Medical records of enrolled patients were reviewed retrospectively.RESULTS:
Serum ferritin levels were 4,677.8+/-1,130.9 microgram/L at baseline compared to 3,363.9+/-1,149.7 microgram/L at the end of deferiprone treatment (P=0.033). Only 1 patient developed neutropenia as a complication.CONCLUSION:
Deferiprone treatment is relatively safe for pediatric patients suffering from various hematologic and oncologic diseases that require RBC transfusions as part of treatment. However, the potential development of critical complications such as agranulocytosis and/or neutropenia remains a concern.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Piridonas
/
Estresse Psicológico
/
Prontuários Médicos
/
Sobrecarga de Ferro
/
Agranulocitose
/
Ferritinas
/
Ferro
/
Neutropenia
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Inglês
Revista:
Korean Journal of Hematology
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS